Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...
Zacks.com on MSN1d
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalShares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...
Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Blood cancer cases are rising alarmingly among young Indians, with leukemia incidences increasing and bone marrow transplants ...
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...
IN8bio, Inc. is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell-based immunotherapies for cancer treatment ... advancements in its INB-100 program for Acute Myeloid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback